Top 50 Clinical Trial Platform - Late Stage

Pi Health provides an AI-native clinical trial platform that unifies fragmented systems into a single intelligent source of truth. This platform integrates AI validation and operational workflows across EDC, CTMS, and eTMF functions to eliminate manual reconciliation. The result is faster study startup, reduced queries, and quicker database lock for clinical development.

Paradigm is developing a platform that integrates clinical trial management systems to enhance trial efficiency and reduce participation barriers for both patients and healthcare providers. By creating a unified infrastructure, Paradigm aims to provide equitable access to clinical trials, accelerating the delivery of potentially life-saving therapies.

The startup has developed a biotech platform that integrates a network of clinical trial sites within existing medical practices, utilizing a mobile cohort of certified research coordinators and advanced software to enhance participant recruitment for research studies. This approach increases access to diverse human subjects for clinical trials, psychological research, and focus groups, addressing the challenge of limited participant availability in traditional drug development processes.

Medable provides a digital platform for decentralized clinical trials that utilizes patient-generated data to enhance participant recruitment and streamline data collection. By integrating tools for remote scheduling, consent management, and real-time reporting, the platform improves the efficiency and quality of clinical research across over 60 countries.

ConcertAI is an AI-driven platform that utilizes real-world data and advanced analytics to enhance clinical trial design and execution in oncology. The company addresses the inefficiencies in cancer research by providing biopharma partners with actionable insights to accelerate drug development and improve patient outcomes.

Iterative Health accelerates gastrointestinal and hepatology clinical trials with an AI-powered platform and specialized services. The company optimizes clinical research sites to improve patient recruitment and site activation, reducing trial timelines.

The startup operates an integrated research organization that embeds clinical trials at the point of care, collaborating with healthcare providers to enhance patient participation and streamline data collection. This approach reduces the drug development timeline, improving access to clinical trials and outcomes for healthcare organizations.

ObvioHealth offers the ObvioGo® 2.0 platform, which utilizes digital tools for real-time data capture and participant engagement in clinical trials. This technology addresses inefficiencies in traditional trial management by providing customizable study designs and enhancing data accuracy, resulting in faster recruitment and improved compliance.

Teckro provides a data-driven platform that enhances site engagement in clinical trials through real-time analytics and targeted interventions. By quantifying site performance, Teckro improves recruitment rates and accelerates study timelines, delivering measurable outcomes for pharmaceutical and biotech sponsors.

H1 provides a health data platform that utilizes AI-enabled analytics to connect life sciences companies with healthcare professionals, enhancing clinical trial design and patient access. The platform addresses the challenge of identifying suitable investigators and optimizing diversity in clinical trials by delivering precise data insights and performance metrics.

Lindus Health operates as an anti-CRO, utilizing a proprietary software platform and access to 30 million Electronic Health Records to execute end-to-end clinical trials with fixed pricing and milestone-based payments. By streamlining study design, patient recruitment, and data management, Lindus delivers trials up to three times faster than traditional CROs, ensuring timely access to new treatments for patients.

The startup offers a remote patient research platform that integrates validated studies and connects with wearables and medical devices, facilitating seamless data transfer into existing systems. This technology enables biopharma and home health professionals to efficiently design and scale clinical research programs while ensuring compliance with data requirements.

Vedadata provides an AI‑powered platform that aggregates and enriches global provider, clinician, site, and patient data into a unified, searchable database. The solution delivers real‑time insights and intelligent search tools for clinical trial planning, medical affairs engagement, commercial targeting, and health‑plan provider management, enabling faster, more accurate outreach and decision‑making.

Curebase provides decentralized clinical research software that enables efficient data collection through electronic patient-reported outcomes (ePRO) and electronic consent (eConsent) systems. The platform enhances participant engagement and accelerates study launches while ensuring high-quality data capture across diverse clinical trials.

Zephyr AI utilizes an AI-enabled platform that integrates diverse healthcare and biological data to identify optimal patient-drug matches and enhance clinical trial efficiency. This approach addresses the challenges of patient stratification and drug development costs, ultimately improving patient outcomes through personalized therapies.

Owkin provides an AI-driven platform that integrates multimodal patient data from a federated network of hospitals to generate and test drug discovery hypotheses at scale. Its autonomous AI Scientist, K Pro, identifies biomarkers, matches therapies to patient subpopulations, and optimizes clinical trial design, continuously learning from real‑world outcomes to accelerate biopharma development.

Formation Bio offers an AI‑native platform that acquires clinical‑stage drug assets and accelerates their development through machine‑learning‑driven candidate scoring, automated trial design, and real‑time risk analytics. The cloud‑based solution integrates multi‑omics data, regulatory intelligence and secure collaboration tools, enabling pharmaceutical, biotech and academic partners to shorten milestones while generating revenue via licensing, milestone payments and royalties.

Truveta aggregates de-identified EHR data, clinical notes, and images from numerous health systems to create a large, representative real-world data asset. This platform supports life science, public health, and healthcare organizations in safety monitoring, HEOR studies, and clinical trial optimization. The company provides powerful analytics, including a proprietary language model, to accelerate therapy adoption and improve care quality.

Ribbon Health provides an AI‑powered data platform that aggregates and continuously updates global information on healthcare professionals, providers, facilities, and patients. The platform offers searchable profiles, real‑time intelligence streams, and master data management tools via APIs, enabling faster clinical trial site selection, targeted medical and commercial outreach, and accurate provider directory management for pharma, biotech, CROs, health plans, and digital health companies.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

Noetik develops frontier AI models trained on extensive multimodal tumor data to predict individual patient responses to cancer treatments. This platform enhances clinical trial enrichment by accurately identifying likely responders for specific therapies. The technology aims to improve drug positioning and accelerate the discovery of novel, human-relevant oncology targets.

Unlearn.ai develops machine-learning models that create digital twins of clinical trial participants, enabling the use of synthetic patient data to enhance control groups. This technology accelerates clinical trials by allowing smaller study designs while maintaining statistical power, ultimately reducing the time and cost associated with bringing new therapies to market.

This biotech startup utilizes a computational discovery engine to develop next-generation immunology nanobodies, enabling the creation of therapeutics with differentiated profiles at scale. By automating clinical trials, the company significantly reduces trial costs and enhances efficiency in drug development.

Lightship utilizes inclusive technology and flexible visit options to enhance patient participation in clinical trials, removing geographic barriers and providing personalized support throughout the research process. This approach addresses the limited access and choice often faced by patients and providers, accelerating the development of new therapies for diverse populations.

Basecamp Research provides a cloud‑based platform that unifies the research workflow, enabling users to design studies, recruit participants, manage consent, and capture data through a drag‑and‑drop builder. The system offers secure, GDPR/CCPA‑compliant storage, real‑time analytics with built‑in statistical tools, and API integration for exporting results to external pipelines.

Enable Medicine provides a cloud‑based platform that consolidates multimodal biological data—such as single‑cell, spatial, omics, imaging, and clinical metadata—into a unified atlas. Using proprietary AI/ML methods, including graph neural networks and spatial deep learning, the platform generates interpretable insights for target identification, biomarker discovery, patient stratification, and trial design, helping biopharma and academic researchers accelerate therapeutic development.

Nucleai has developed an AI-powered platform that utilizes military-grade geospatial analysis to interpret complex cellular interactions in biopsy samples, generating spatial biomarkers for precision medicine. This technology enhances drug development by providing actionable insights that improve patient selection for clinical trials and optimize treatment strategies.

Mendel is an AI platform that combines large language models with a clinical hypergraph to enable physician-level cognitive reasoning for analyzing structured and unstructured clinical data. It enhances clinical data workflows by providing accurate cohort retrieval and chart review, ensuring outputs are explainable and grounded in a coherent patient journey.

DBV Technologies develops the VIASKIN® patch, an epicutaneous immunotherapy (EPIT) platform that delivers tiny amounts of allergen to the skin to re‑educate the immune system. The patch is being tested in clinical trials for peanut and milk allergies, aiming to provide a safer, long‑term treatment option for patients with food allergies.

Develops a telemonitoring platform combining a clinical decision support system for oncologists and a mobile application for cancer patients, enabling remote tracking of treatment progress and adverse events. This solution improves patient quality of life, treatment adherence, and survival rates while streamlining care coordination in over 90 healthcare institutions.

Tasso provides a needle‑free, self‑administered blood collection system that lets patients draw capillary blood at home using single‑use Tasso+ or Tasso Mini devices. The company handles end‑to‑end logistics—including kit shipping, live remote guidance, prepaid return shipping, and a cloud portal or API for sample tracking and results—enabling healthcare providers and researchers to run decentralized trials and frequent at‑home sampling without in‑person phlebotomy.

AllStripes utilizes a Universal Patient Record powered by PicnicAI to streamline observational research and enhance patient care for rare diseases. The platform reduces research costs by 30-50% and accelerates patient enrollment, achieving a 98% retention rate year over year.

Eikon Therapeutics offers a platform that combines high‑throughput single‑molecule imaging with deep‑learning analytics to produce quantitative molecular maps of cancer and neuro‑degenerative pathways. The system prioritizes therapeutic targets, predicts efficacy, and supports biomarker generation for immune‑modulation and synthetic‑lethality programs, delivering data packages ready for IND‑enabling studies. The platform is licensed to pharmaceutical, biotech, and academic partners for target discovery and preclinical development.

Immunai utilizes multi-omic single-cell analysis and machine learning to enhance drug development by optimizing clinical trials and evaluating preclinical assets. The company addresses the challenge of identifying effective treatment regimens and critical targets in human diseases, facilitating the advancement of immunomodulatory therapies.

Alto Neuroscience develops precision medicines for neuropsychiatric conditions using an AI-driven biomarker platform to predict clinical responses and identify patients most likely to benefit from their drug candidates. Their focus on major depressive disorder, bipolar depression, and schizophrenia aims to replace the trial-and-error approach in psychiatric treatment with targeted therapies based on deep neurobiological insights.

BioAge provides a cloud‑based platform that generates multi‑omics biomarkers to quantify an individual’s biological age and predict health‑span trajectories. The service integrates genomics, transcriptomics, proteomics and metabolomics data with machine‑learning models, delivering calibrated age scores via a HIPAA‑compliant API and web dashboard for use by clinicians and pharmaceutical trial teams to personalize interventions and stratify study cohorts.

Dizal Pharma provides end‑to‑end outsourced services for drug development and manufacturing, covering everything from early‑stage formulation and clinical trial material production to commercial‑scale GMP manufacturing. Their integrated platform combines formulation science, process optimization, regulatory support, analytical testing, and supply‑chain logistics to accelerate time‑to‑market while ensuring compliance and consistent product quality for pharma innovators, biotech firms, and generic manufacturers.

Iterative Scopes provides real-time AI tools for colorectal cancer screening and surveillance, enhancing diagnostic accuracy for physicians. The platform aims to improve patient outcomes in gastrointestinal care by leveraging machine learning to optimize clinical research practices and treatment protocols.

BrightInsight provides a regulated digital health platform that enables biopharma and medtech companies to develop and manage Software as a Medical Device (SaMD) solutions, including companion apps and connected products. The platform enhances patient care by delivering measurable clinical and business outcomes, improving patient adoption and retention across various therapy areas.

Atropos Health develops a cloud-based Evidence Platform that converts electronic medical record data into high-quality Real-World Evidence, enabling healthcare organizations to make data-driven clinical decisions. This platform addresses the issue of insufficient evidence backing medical decisions, significantly reducing the time and resources required to generate actionable insights for patient care and research.

Scholar Rock develops biologic and small‑molecule agents that modulate growth‑factor proteins before activation, aiming to intervene early in disease pathways. Its platform supports a pipeline across neuromuscular, cardiometabolic, immuno‑oncology, and fibrotic indications, with integrated preclinical, IND‑enabling, and clinical development and collaborations for expanded‑access studies.

Alector uses a genetics‑first platform to identify protein pathways linked to neurodegeneration and develops CNS‑penetrant therapeutics—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—that clear toxic aggregates or modulate microglial activity. Its programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate development of disease‑modifying treatments for Alzheimer’s disease, frontotemporal dementia, and ALS.

Every Cure uses AI-driven analysis of existing drug and disease data to identify repurposing opportunities. It advances the most promising candidates through preclinical and clinical development to address unmet medical needs. The organization aims to expand patient access to affordable, effective therapies by leveraging already approved medications.

Huma provides a regulated cloud platform for building and deploying AI-first digital health applications, including remote patient monitoring and Software as a Medical Device (SaMD) solutions. The platform accelerates the creation of health super apps and virtual care models, enhancing clinical efficiency and patient outcomes through integrated AI capabilities and global regulatory compliance.

Vesalius Therapeutics employs a proprietary platform that utilizes patient-derived, cell-based experimental models and advanced data analytics to identify novel drug targets for complex diseases like heart failure and type II diabetes. By recognizing distinct clinical patterns linked to genetic variations, the company aims to develop targeted therapies that address the multifaceted nature of these prevalent illnesses.

PicnicHealth provides an AI-driven platform that aggregates, digitizes, and normalizes medical records from any U.S. provider into a unified, searchable patient timeline. The mobile app lets patients view and share their complete health history, while an API supplies life‑science companies with high‑density, de‑identified longitudinal data for real‑world evidence studies.

Wugen produces off‑the‑shelf allogeneic CAR‑T cell therapies using CRISPR/TALEN editing to delete T‑cell receptor and HLA loci, creating a universal, cryopreservable product that can be shipped to treatment centers on demand. The platform supports a pipeline of CD7‑targeted candidates for T‑cell acute lymphoblastic leukemia, T‑cell non‑Hodgkin lymphoma, acute myeloid leukemia and selected autoimmune diseases, and includes an inducible safety switch for rapid cell ablation. By eliminating patient‑specific manufacturing, the approach reduces time‑to‑treatment and manufacturing costs while expanding access to cellular immunotherapy.

The startup has developed a healthcare application that connects patients with specialized doctors to provide personalized care for complex issues and chronic illnesses. This platform enables patients to receive tailored medical attention remotely, ensuring they have access to the right expertise from any device.

Acrivon uses its proprietary AP3 proteomics platform to create quantitative OncoSignature tests that directly measure tumor‑driving protein pathways from biopsy samples. These tests serve as companion diagnostics to match patients with Acrivon's kinase inhibitor candidates, improving patient selection and accelerating clinical development for oncology drug developers.

The startup provides genomic medicine delivery by connecting individuals and healthcare providers with genetic experts for personalized genetic assessments and clinical action plans. This approach enables patients to make informed treatment decisions while facilitating faster disease diagnosis for medical practitioners at reduced costs.